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Background: Patients with bipolar disorder often show decreased adherence with mood stabilizers and frequently
interventions on prodromal depressive and manic symptoms are delayed.
Recently, the MONARCA I randomized controlled trial investigated the effect of electronic self-monitoring using
smartphones on depressive and manic symptoms. The findings suggested that patients using the MONARCA
system had more sustained depressive symptoms than patients using a smartphone for normal communicative
purposes, but had fewer manic symptoms during the trial. It is likely that the ability of these self-monitored
measures to detect prodromal symptoms of depression and mania may be insufficient compared to automatically
generated objective data on measures of illness activity such as phone usage, social activity, physical activity, and
mobility. The Monsenso system, for smartphones integrating subjective and objective measures of illness activity
was developed and will be tested in the present trial.
Methods: The MONARCA II trial uses a randomized controlled single-blind parallel-group design. Patients with
bipolar disorder according to ICD-10 who previously have been treated at the Copenhagen Clinic for Affective
Disorder, Denmark are included and randomized to either daily use of the Monsenso system including an feedback
loop between patients and clinicians (the intervention group) or to the use of a smartphone for normal
communicative purposes (the control group) for a 9-month trial period. The trial was started in September 2014
and recruitment is ongoing. The outcomes are: differences in depressive and manic symptoms; rate of depressive
and manic episodes (primary); automatically generated objective data on measures of illness activity; number of
days hospitalized; psychosocial functioning (secondary); perceived stress; quality of life; self-rated depressive
symptoms; self-rated manic symptoms; recovery; empowerment and adherence to medication (tertiary) between
the intervention group and the control group during the trial. Ethical permission has been obtained. Positive,
neutral and negative findings will be published.
Discussion: If the system is effective in reducing depressive and/or manic symptoms (and other symptoms of
bipolar disorder) and the rate of episodes, there will be basis for extending the use to the treatment of bipolar
disorder in general and in larger scale.
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Patients with bipolar disorder often show decreased ad-
herence with mood stabilizers [1-3] and frequently inter-
vention on prodromal depressive and manic symptoms is
delayed [4,5]. During recent years there have been an in-
creasing growth of e-mental health technologies [6], and
the amount of electronic platforms for self-monitoring in
mental health, including bipolar disorder, is increasing
rapidly. Recently, electronic self-monitoring of depressive
and manic symptoms using regular cell phones to
prompt patients with bipolar disorder to respond to
weekly text messages has been suggested as an easy and
inexpensive way to continuously monitor and identify
prodromal depressive and manic symptoms and in this
way allowing for health care providers to intervene
shortly after symptoms first appear [7].
Other articles reporting on electronic self-monitoring
have used personal digital assistants (PDAs) [8,9], com-
puters [10-18] and smartphones [19] as the electronic
self-monitoring tools, but none of the studies have how-
ever included data on objective measures of illness activ-
ity and the effect of electronic self-monitoring has only
been investigated sparingly in randomized controlled tri-
als (RCT) [20]. It is likely that the ability of these elec-
tronically self-monitored subjective measures may not
be sufficient to detect prodromal depressive and manic
symptoms compared to automatically generated behav-
ioural data on measures of illness activity (objective
measures) such as phone usage, social activity, physical
activity, and mobility. Social activity [21], i.e., engaging
in relations to others, as well as physical activity [22-24]
represent central and sensitive aspects of illness activity
in bipolar disorder, but none of the articles used patients
monitored during non-experimental daily life, in natural-
istic settings and with collection of real-time data.
Our group developed and tested the MONitoring,
treAtment and pRediCtion of bipolAr disorder epi-
sodes system (the MONARCA system), an Android
smartphone-based electronic self-monitoring system,
in a number of studies during recent years [25-28].
The MONARCA system allowed for electronic subject-
ive self-monitoring of mood, sleep, activity level, irrit-
ability, stress, medicine intake, alcohol consumption
and other subjective personal measures and included a
bi-directional feedback loop between patients and
health care providers. The system also collected auto-
matically generated behavioural data on measures ofillness activity, such as accelerometer data, the number
of incoming and outgoing phone calls/ day, and the
number of incoming and outgoing text messages/ day
[27].
The initial MONARCA pilot studies showed a high
acceptance of the system and a higher compliance to self-
monitoring than when monitoring on a paper-based
version [25-28]. Further studies showed that electronic
self-monitoring of depressive and manic symptoms using
the MONARCA system correlated with observer-based
clinically rated depressive and manic symptoms using the
Hamilton Depression Rating Scale 17 item (HDRS-17)
[29] and the Young Mania Rating Scale (YMRS) [30], re-
spectively. Furthermore, HDRS-17 and YMRS correlated
with a number of automatically generated behavioural
data on measures of illness activity collected by the smart-
phone (e.g. the number and duration of incoming and
outgoing calls/day and the number of outgoing text-
messages/day) [28,31].
The MONARCA I RCT investigated the effect of daily
electronic self-monitoring of subjective measures using
the MONARCA system including a bi-directional feed-
back loop between the patient and clinicians compared
with using a smartphone for normal communicative
purposes in patients with bipolar disorder [20]. Overall
no differences between the intervention group and the
control group was found, but findings from sub-analyses
suggested that patients using the MONARCA system
had more sustained depressive symptoms than the con-
trol group and fewer manic symptoms in periods with
presence of manic symptoms [20].
It has never been tested in a RCT whether electronic
self-monitoring of subjective measures including a feed-
back loop integrating subjective as well as automatically
generated behavioural data on measures of illness activity
in patients with bipolar disorder improves illness outcome.
Hypotheses
Using a smartphone-based monitoring system for daily
electronic self-monitoring including an integrated feed-
back loop on both subjective and automatically generated
behavioural data on measures of illness activity (phone
usage, social activity, physical activity, and mobility) (the
Monsenso system) reduces the severity of depressive and
manic symptoms and rate of depressive and manic epi-
sodes in adult patients with bipolar disorder more than
standard treatment.
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To investigate in a randomized controlled single-blind
parallel-group trial whether the use of a smartphone-
based monitoring system including an integrated feed-
back loop on both subjective and automatically generated
behavioural data on measures of illness activity (phone
usage, social activity, physical activity, and mobility), the
Monsenso system, reduces depressive and manic symp-
toms, the rate of depressive and manic episodes, the total
number of days hospitalized, and improves psychosocial
function, perceived stress, quality of life, self-rated
depressive symptoms, self-rated manic symptoms, re-
covery, empowerment, and medicine adherence more
than standard treatment in adult patients with bipolar
disorder.
Methods
The trial protocol is reported according to the CONsoli-
dated Standards Of Reporting Trials (CONSORT) state-
ment and Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) [32-34].
The trial protocol describes a randomized controlled
single-blind parallel-group trial investigating the effect of
using the Monsenso system on a daily basis, this includ-
ing an integrated feedback loop, compared with using a
smartphone for normal communicative purposes in
adult patients with bipolar disorder.
Trial design and study organization
The MONARCA II trial is a randomized controlled
single-blind parallel-group trial with an unbalanced allo-
cation ratio (2:1) of adult patients with bipolar disorder.
The included patients are randomized to either active use
of the Monsenso system on either an smartphone capable
of collecting automatically generated behavioural data on
measures of illness activity (e.g. Android smartphones) or
an smartphone not capable of collecting automatically
generated behavioural data on measures of illness activity
(e.g. iPhone) (which type of smartphone used is chosen
by the patients themselves, and is estimated to be ap-
proximately 50% on each of these types of smartphones)
(the intervention group) or to the use of a smartphone
for normal communicative purposes (the control group).
The flow diagram of the MONARCA II trial is presented
in Figure 1.
The study is conducted at the Psychiatric Center
Copenhagen, Rigshospitalet, Copenhagen, Denmark. No
changes in study design or methods have been made after
trial commencement.
Participants and settings
All patients with a diagnosis of bipolar disorder accord-
ing to ICD-10 who have been treated and discharged
from The Copenhagen Clinic for Affective Disorder,Denmark in the period 2004 to January 2016 are invited
to participate in the trial. This corresponds to approxi-
mately 400 potential participants. The Copenhagen Clinic
for Affective Disorder is a specialized outpatient clinic that
covers a recruitment area of the Capital Region, Denmark,
corresponding to 1.4 million people. The staff consists of
full-time specialists in psychiatry with a specific clinical
experience and knowledge about the diagnosis and treat-
ment of bipolar disorder as well as certified psychologist,
nurses and a social worker with experience in bipolar dis-
order. Patients with bipolar disorder were referred to the
Copenhagen Clinic for Affective Disorder from secondary
healthcare when a diagnosis of a single mania or bipolar
disorder was made for the first time or in the case of oc-
currence of treatment resistance (persistent depressive or
manic symptoms or recurrence despite treatment in
standard care). The physicians at the clinic followed the
patients with evidence-based psychopharmacological
treatment and regular appointments. Treatment at the
Copenhagen Clinic for Affective Disorder comprised com-
bined psychopharmacological treatment as according to
the guidelines from the British Association for Psycho-
pharmacology [35] and supporting therapy for a 2-year
period [36].
Inclusion criteria: All patients between the age of 18
to 75 years with a bipolar disorder diagnosis according
to ICD-10 using Schedules for Clinical assessments in
Neuropsychiatry (SCAN) [37] who have been treated and
discharged from The Copenhagen Clinic for Affective
Disorder, Denmark from the period 2004 to January 2016
are invited to participate in the MONARCA II trial.
Exclusion criteria: Patients who have received the
MONARCA system as part of previous studies are ex-
cluded. Patients who are pregnant and with a lack of
Danish language skills are excluded.
Patients meeting the inclusion criteria and having
none of the exclusion criteria are invited to be enrolled
in the MONARCA II trial.
Study procedure
Potential participants are invited to participate in the
MONARCA II trial first by mail, then by phone calls and
lastly by e-mail if no responses are received via the first
two methods. All potential participants who accept to
meet with the researcher (MFJ) for further trial informa-
tion are screened if they fulfill the criteria for participation
and then included in the MONARCA II trial. Following
inclusion, baseline assessments are performed on all pa-
tients and after these assessments are the numbered
opaque allocation envelopes distributed by a research
secretary (HGN) to the MONARCA II study nurse and
the patients are randomized to either the intervention
group or the control group for a 9-month trial period. An
overview of the assessments is presented in Table 1.
Figure 1 The MONARCA II- Flow Diagram.
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All included patients have received treatment and have
been discharged from The Copenhagen Clinic for AffectiveDisorder, Denmark during the period from 2004 to January
2016 at inclusion in the present MONARCA II trial. All in-
cluded patients continue their treatment as usual at a
Table 1 Outcome assessment overview- The MONARCA II trial
SCANa Baseline characteristics Rating scalesb Questionnairesc Clinical informationd Biological samplese
Inclusion and baseline x x X X x X
Randomization (2:1) to using a smartphone with the MONARCA II system (the intervention group) or to use a smartphone for normal communicative
purposes (the control group)
4 weeks X X x X
3 months X X x X
6 months X X x x
9 months X X x x
aSchedules for Clinical Assessment in Neuropsychiatry interview (37).
bDepressive symptoms according to Hamilton Depression Rating Scale 17-item (29), manic symptoms according to Young Mania Rating Scale (30) and
psychosocial functioning according to Functioning Assessment Short Test (FAST) (38).
cPerceived stress according to Cohen’s Perceived Stress scale (39), quality of life according to WHO Quality of Life-BREF (WHOQOL-BREF) (40), self-rated depressive
symptoms according to Becks Depressive Inventory (BDI) (41–43), self-rated manic symptoms according to Altman Self Rating scale for Mania (ASRM) (44), recovery
according to Recovery Assessment Scale (45), empowerment according to Rogers empowerment scale (47) and medicine adherence according to Medicine
Adherence Rating Scale (MARS) (46).
dNumber of affective episodes, number of contacts to clinicians and psychiatric emergency rooms, number of hospitalizations, medication status etc.
eBlood samples is obtained by venipuncture, 90 ml in total and a freshly voided spot urine sample is collected.
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eral practitioner or outpatient treatment at a hospital dur-
ing the trial period.
The MONARCA studies
Following the MONARCA studies adjustments to the
self-monitoring part of the system were made and a new
integrated feedback loop, based on prediction models
including both subjective measures and automatically
generated behavioural data on measures of illness activ-
ity, was established. This is the Monsenso system, and
the effect of this is investigated in the present MON-
ARCA II trial.
The smartphones
In the MONARCA II trial the Monsenso system is
available for smartphones capable of collecting auto-
matically generated behavioural data on measures of
illness activity (e.g. different versions of Android smart-
phones) or smartphones not capable of collecting auto-
matically generated behavioural data on measures of
illness activity (e.g. iPhones). All patients are, regardless
of randomization allocation, offered to loan an Android
smartphone free of charge for the 9-month trial period.
The patients, regardless of randomization allocation,
who are using a smartphone not capable of collecting
automatically generated behavioural data on measures
of illness activity beforehand and do not want to loan
and use the Android smartphones offered by the MON-
ARCA II trial, are offered to use their own smartphones
for the 9-month trial period.
The patients in the intervention group have to use the
Monsenso system for daily electronic self-monitoring,
and the patients in the control group have to use the
smartphones for normal communicative purposes. This
is regardless the choice of smartphone type. Both theintervention group and the control group have to use the
smartphones for the 9-month trial period. Economic
costs from data traffic due to the MONARCA II trial are
refunded to all participants regardless of randomization
allocation and choice of smartphone type.
Subjective (self-monitored) measures of illness activity in
the intervention group
The patients randomized to the intervention group, re-
gardless the choice of smartphone, are prompted by an
alarm in the Monsenso system at a self-chosen time dur-
ing the day to evaluate subjective measures of illness
activity on a daily basis. The following subjective (self-
monitored) measures of illness activity are available for
daily evaluation: mood (scored from depressive to manic
on a scale from −3, −2, −1, −0.5, 0, +0.5, +1, +2, +3), sleep
duration (number of hours slept per night, measured in
half-hour intervals), medicine intake (taken as prescribed/
taken with changes (if changes, the patients are asked to
specify these)/not taken), activity level (scored from very
low to very high on a scale from −3, −2, −1, 0, +1, +2, +3),
mixed mood (yes/no), irritability (scored from not present,
present to some degree or present on a scale from 0, 1, 2),
anxiety (scored from not present, present to some degree
or present on a scale from 0, 1, 2), cognitive problems
(scored from not present, present to some degree or
present on a scale from 0, 1, 2), alcohol consumption
(number of units consumed per day, 0 to +10 scale), stress
(scored from not present, present to some degree or
present on a scale from 0, 1, 2), menstruation for women
(yes/no), individual early warning signs (yes/no), a number
(unlimited) of personal parameters (created by the pa-
tients themselves), and a free-text note.
After midnight, the entered subjective (self-moni-
tored) measures of illness activity are “locked” and fur-
ther changes cannot be made. If the patients wish to
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ond evaluation in addition to the initial one, and both of
the subjective evaluations are then visible for the patient
and the health care provider when logging on to in the
Monsenso system. If the patients forget to evaluate the
subjective measures it is possible to enter and evaluate
retrospectively for up to two days. It is then noted in the
Monsenso system that the subjective measures are col-
lected retrospectively. Screenshots from the Monsenso
software are presented in Figures 2 and 3. A user’s guide
for the Monsenso system was developed and is handed
out to all patients in the intervention group (can be ob-
tained by contacting the first author).
Automatically generated behavioural data (objective data)
on measures of illness activity in both the intervention
group and the control group
All of the smartphones capable of collecting automatic-
ally generated behavioural data on measures of illnessFigure 2 The Monsenso system, dashboard.
Figure 3 The Monsenso system, self-monitored mood.activity regardless of randomization group (intervention
group or control group) collects as many automatically
generated behavioural data on measures of illness activ-
ity (objective data) on a daily basis during the 9-month
trial period as possible (different smartphones hardware
and operating systems support different types of sen-
sors) (Figure 1).
Examples of some of the automatically generated behav-
ioural data on measures of illness activity collected by the
smartphones: 1) phone usage measured as the amount of
time the smartphones screen are turned on/off, battery
usage, ambient light, and ‘proximity’ detection 2) social ac-
tivity measured as the number of in- and outgoing phone
calls and text messages, the duration of in- and outgoing
phone calls, the length of the text messages, and the time
of the day when the phone calls and/or text messages are
made/send/or received 3) physical activity measured by the
step counter in the smartphones, and 4) mobility based on
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again rely on e.g. GPD or GSM cell tower information
depending on specific circumstances). Furthermore, speech
activity is collected by extraction of different voice features
during phone calls. Voice feature extraction will take place
directly on the smartphones and no recording of the actual
speech/conversation will take place.
Thus, we will be able to investigate correlations be-
tween automatically generated behavioural data on mea-
sures of illness activity and the severity of depressive and
manic symptoms of all participants in the trial, using
smartphones capable of collecting automatically gener-
ated data on measures of illness activity, including the
ones allocated by randomization to the control group.
The integrated feedback loop between patients and
clinicians in the intervention group
A study nurse with experience with bipolar disorder is
assigned to the patients allocated to the intervention
group of the MONARCA II trial. The MONARCA II
study nurse is responsible for the integrated feedback
loop. Patients allocated to the intervention group of the
MONARCA II trial have the Monsenso application in-
stalled on a smartphone, and this automatically transfers
the self-monitored subjective measures and for some
smartphones also the automatically generated behav-
ioural data on measures of illness activity (Flow diagram
in Figure 1) to servers at the hospital through secure
connections (I-suite number RHP-2011-03). By giving
informed consent to participate in the MONARCA II
trial, the patients allow for the MONARCA II study
nurse and their health care provider to access the moni-
tored data through a secure web interface. The MON-
ARCA II study nurse goes through the collected data two
to three times a week, or more often on patients where it
is deemed necessary. A personal homepage is set up on a
server allowing for the patients to access all their own
data through a similar secure web interface.
1) The feedback loop on subjective measures:
Regardless the choice of smartphone a feedback loop
on the subjective measures is established. A standard
of scoring thresholds for when the MONARCA II
study nurse initially should react was made. For
example, the MONARCA II study nurse reacts if the
patients register ≥ −2 on the mood item for two days
or more, or if the patients register changes in their
sleep patterns of 1 hour or more for more than
three days. Following a run in phase of
approximately two to four weeks of self-monitoring,
the patients and the MONARCA II study nurse
individualize the thresholds for when reaction
should be made. Also the MONARCA II study
nurse and the patients agree on a concordancestatus in a) the patients most important items for
identifying prodromal symptoms of depression as
well as (hypo)mania b) the threshold for future early
warning signs c) actions to be taken in case of
depression or (hypo)mania.
2) The integrated feedback loop on subjective and
automatically generated behavioural data on
measures of illness activity: A feedback loop
integrating subjective and automatically generated
behavioural data on measures of illness activity is
established for patients using smartphones capable
of collecting automatically generated data on
measures of illness activity (Figure 1). The feedback
loop integrates both subjective and automatically
generated behavioural data on measures of illness
activity in a flexible and adjustable model (a learning
system) resulting in prediction analyses of the
collected data providing messages for both the
patients and the MONARCA II study nurse such as:
“you should contact the MONARCA II study nurse”.
Actions by the study nurse as part of the feedback loop
in the intervention group: In the case of signs of deterior-
ation of a patient the MONARCA II study nurse a) con-
tacts the patient and give advice on how to handle the
situation b) (if the first action is not enough) asks the pa-
tient to contact his/her usual physician or other clinician
c) (if the above actions are not enough, or if contact to
the patient is not possible) contacts the patient’s usual
physician or other clinician d) (if acute deterioration and/
or severe symptoms) contacts the psychiatric emergency
service in Copenhagen, Denmark.
Assessments
All assessments are carried out by one researcher (MFJ)
who is not involved in the treatment of the patients. The
bipolar disorder diagnoses according to ICD-10 are con-
firmed by a SCAN interview before inclusion of the pa-
tients. The patients are, regardless of randomization group,
enrolled for a 9-month trial period and invited for outcome
assessments by a blinded researcher (MFJ) at baseline, after
4 weeks, after 3 months, after 6 months and after 9 months
(Table 1).
At each visit with the researcher the assessments include
the following: The severity of depressive and manic symp-
toms is measured using HDRS-17 item and YMRS, re-
spectively, and psychosocial functioning is measured using
the Functioning Assessment Short Test (FAST) [38]. The
following questionnaires are fulfilled when visiting the re-
searcher: perceived stress according to Cohen’s Perceived
Stress scale [39], quality of life according to WHO Quality
of Life-BREF (WHOQoL-BREF) [40], self-rated depressive
symptoms according to Becks Depressive Inventory (BDI)
[41-43], self-rated manic symptoms according to Altman
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ing to Recovery Assessment Scale (RAS) [45], medicine
adherence according to Medicine Adherence Rating Scale
(MARS) [46] and empowerment according to Rogers Em-
powerment Scale (RES) [47].
Furthermore, the patients are asked to show up fasting
between 8–10 A.M. at baseline, after 4 weeks, 3 months,
6 months and 9 months when visiting the researcher and
the following biological samples are collected: 1) Blood
samples obtained by venipuncture, 90 ml in total and 2) a
freshly voided morning spot urine sample (around 20
ml). The biological samples will be analyzed at the end of
the trial for candidate biological markers that are poten-
tially related to alterations in illness activity and affective
state in bipolar disorder.
Outcomes
Primary outcomes
– Differences in clinically rated depressive and manic
symptoms measured using HDRS-17 and YMRS,
respectively, between the intervention group and the
control group.
– Differences in depressive and manic symptoms
measured using HDRS-17 and YMRS,
respectively, between the intervention group and the
control group in patients with presence of
depressive and manic symptoms (defined as HDRS-
17 > 0 or YMRS > 0) at any given visit with the re-
searcher during the 9-month trial period.
– Differences in depressive and manic episodes defined
as HDRS-17 ≥14 or YMRS ≥14 between the
intervention group and the control group.
Secondary outcomes
– Differences in automatically generated behavioural
data (objective data) collected from the smartphones
(e.g. mobility, social and physical activity etc.)
between the intervention group and the control
group.
– Differences in the total number of days hospitalized
between the intervention group and the control
group.
– Differences in psychosocial functioning according to
the FAST score between the intervention group and
the control group.
Tertiary outcomes
Differences in perceived stress according to Cohen’s
Perceived Stress scale, quality of life according to the
WHOQOL-BREF score, self-rated depressive symptoms
according to BDI, self-rated manic symptoms according to
ASRM, recovery according to the Recovery AssessmentScale, empowerment according to Rogers Empowerment
Scale and medicine adherence according to MARS be-
tween the intervention group and the control group.
No changes in trial outcomes have been made after
trial commencement.
Statistical power and sample size calculation
The statistical power and sample size was calculated
using http://stat.ubc.ca/~rollin/stats/ssize/n2.html.
The primary outcomes are a) differences in the level of
depressive and manic symptoms based on HDRS-17 and
YMRS, respectively and b) differences in the number of
depressive and manic episodes defined as HDRS ≥14
and YMRS ≥14, respectively.
a) The clinical relevant difference in the level of
depressive and manic symptoms is defined as a
minimum of three scores on HDRS-17 and YMRS,
respectively, and the standard deviation (SD) is set
to 7 with a mean score of 7 vs. 10 in the
intervention group and the control group,
respectively. The statistical power to detect a three
score difference in the areas under the curves
between the intervention group and the control
group on HDRS-17 and YMRS, respectively, is 80%
with α = 0.05 for a two-sample comparison of means
including a minimum of 86 patients in each of the two
sub-groups in the intervention group (smartphones
capable of collecting automatically generated
behavioural data or not) (n = 172) and 86 patients in
the control group (n = 86). This results in an
estimated total sample size of 258 patients.
b) The clinical relevant difference in the number of
depressive and manic episodes is defined as a
minimum of 10% difference and the SD is set to 23%
with a mean score of 40% vs. 50% in the
intervention group and the control group,
respectively. The statistical power to detect a 10%
difference in the area under the curves between the
intervention group and the control group on the
number of depressive and manic episodes is 80%
with α = 0.05 for a two-sample comparison of means
including about the same number of patients in each
of the two sub-groups in the intervention group
(smartphones capable of collecting automatically
generated behavioural data or not) (n = 172) and in
the control group (n = 86).
Randomization
Sequence generation
A computer-generated list of random allocation num-
bers using randomization.com was carried out by an in-
dependent researcher (KM), who is not a part of the
trial. Patients included in the trial are randomized with
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senso system on a daily basis including the integrated
feedback loop (based on either a) subjective self-
monitored measures alone or 2) a combination of sub-
jective self-monitored measures and automatically
generated behavioural data on measures of illness activity)
(the intervention group) or to the use of a smartphone
for normal communicative purposes (the control group)
(Figure 1). A design with an unbalanced allocation ration
was chosen since the integrated feedback loop using
smartphones capable of collecting automatically generated
behavioural data on measures of illness activity or not is
not based on the same amount of collected data, and thus
comprising two versions of the integrated feedback loop.
The choice of smartphone used is chosen by the patients
themselves at inclusion before the randomization, and
is estimated to by approximately 50% on each of these
types of smartphones (smartphones capable of collecting
automatically generated behavioural data on measures of
illness activity (e.g. different versions of Android smart-
phones) or not (e.g. iPhones)). Thus, a design with an un-
balanced allocation ration of 2:1 will result in three groups
of approximately 86 patients in each group (Figure 1).
Since the MONARCA II trial is single-blinded, ran-
dom block sizes are used to help preserve unpredictabil-
ity [48,49]. The MONARCA II study nurse is unaware of
the range of numbers of patients in the random block
sizes.
Since then gain from stratification becomes minimal
when the number of participants in each group of a trial
is more than 50 [50], but adds complexity, a non-
stratified randomization design was chosen. The statis-
tical analyses will however be adjusted for age and sex as
possible prognostic variables.
Allocation concealment and implementation
The allocation sequence is concealed from the researcher
(MFJ) enrolling and assessing the patients and from the
MONARCA II study nurse. Allocation is concealed in
numbered, opaque and sealed envelopes and stored in a
securely locked cabinet of unknown location to others
than the research secretary (HGN). Allocation is identi-
fied by the letter A or B written on the paper (different
colour of paper for the two different randomization
groups) inside the envelopes and this indicate the alloca-
tion to intervention (intervention group or control
group). The translation of the letters A and B was made
and known to only KM, LVK and the MONARCA II
study nurse. A paper with this translation is kept in a
securely locked cabinet of unknown location to others than
KM and LVK. The secretary (HGN) gives the allocation
envelopes to the MONARCA II study nurse after enrol-
ment and baseline assessments of the patients. Corre-
sponding allocation envelopes are opened only after allbaseline assessments are performed and the patients’
names and social security numbers are written on both
the envelopes and the randomization papers. The MON-
ARCA II study nurse assigns patients to their allocation
of intervention.
Blinding
Owing to the type of intervention in the MONARCA II
trial, the patient, the patients’ health care provider and
the MONARCA II study nurse are aware of the allocated
randomization group. The researchers responsible for
outcome assessments, data entry, data analysis, interpret-
ation of analysis and writing of papers are kept blinded to
allocation at all times during the trial period, data ana-
lysis and interpretation of analysis. The trial is therefore
single-blinded. The MONARCA II study nurse does not
collect any outcome measures. All patients are thor-
oughly and at each visit with the researcher instructed
not to mention anything about randomization allocation.
The risk of unblinding due to simply seeing the patients’
smartphone is minimized since all patients use a smart-
phone during the trial period.
Statistical methods
Data from all randomized patients are collected until
dropout or the end of the trial period. Analysis will be
carried out with an intention-to-treat (ITT) approach.
The primary outcomes are differences in depressive and
manic symptoms using HDRS-17 and YMRS, respect-
ively, during the 9-month trial period. Analysis will be
done employing a linear mixed effects model with ran-
dom intercept for each participant and a fixed effect of
visit number. Differences in outcomes between the inter-
vention group and the control group will be analyzed,
firstly in an unadjusted model (except for potential differ-
ences in baseline values of the outcome variable) and
then in models adjusted for age and sex as possible prog-
nostic variables.
Furthermore, analysis will be done employing a linear
mixed effects model with random intercept for each partici-
pant and a fixed effect of visit on differences in HDRS-17
and YMRS in patients with presence of depressive and
manic symptoms (defined as HDRS-17 > 0 or YMRS > 0) at
a given time point during the trial period between the inter-
vention group and the control group. Additionally, analysis
of the primary outcomes of differences in depressive and
manic episodes defined as HDRS ≥14 and YMRS ≥14 dur-
ing the trial period will be done employing survival analysis
with reasons for censoring being date of death or date of
drop out.
Potential interactions between randomization group
(intervention group or control group) and visit number
in the analyses will be investigated and reported accord-
ingly. The statistical threshold for significance is p ≤ 0.05
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using Epidata® (Epidata Association, Odense, Denmark).
All analyses will be done using STATA version 12 (Stata-
Corp LP, College Station, TX, USA).
Ethical considerations and approval
Ethical permission for the MONARCA II trial has been ob-
tained from the Regional Ethics Committee in The Capital
Region of Denmark and The Danish Data Protection
Agency (H-2-2014-059). The law on handling of personal
data will be respected. The patients’ journals will only be
read to confirm information regarding the patients’ clinical
history. The trial was registered at ClinicalTrials.gov as
NCT02221336 on the 26th of September 2014. Link to
the trial registration: https://clinicaltrials.gov/ct2/show/
NCT02221336?term=MONARCA+II&rank=1. All posi-
tive, neutral and negative findings of the trial will be pub-
lished according to the CONSORT guidelines [32]. All
electronic monitored data are stored at a secure server at
Capital Region, Copenhagen, Denmark. The usual health
care provider/physician/clinician of the patients random-
ized to the intervention group are contacted by letter at
the beginning of the trial and informed about the trial
and that they might get contacted by the MONARCA II
study nurse if there are signs of deterioration of the
patient.
All potential participants are invited to receive infor-
mation about the MONARCA II trial on an individual
basis where the information is given in a quiet and un-
disturbed office. All information is presented in both
written and verbal form and participants can bring a
friend or relative to the introduction conversation. Par-
ticipants are informed that participation is voluntary and
that consent can be withdrawn at any time during the
trial without this having any consequences for current
and future treatment options. All participating patients
sign a consent form and get a copy of this and their
rights as a participant in a clinical trial. All participating
patients are offered to loan a smartphone free of charge
during the trial period, and economic costs due to data
traffic from the Monsenso system are refunded. Partici-
pants do not receive any economic compensation for
participating in the MONARCA II trial.
Results
Recruitment is ongoing.
Discussion
There are yet few studies on electronic self-monitoring in
bipolar disorder, and the evidence of electronic self-
monitoring has been sparingly investigated and is limited
by methodological issues and by a lack of RCTs [51]. Al-
though the idea of electronic self-monitoring seems ap-
pealing, studies using rigorous methodology investigatingbeneficial and possible harmful effects of electronic self-
monitoring are needed.
Our group, consisting of psychiatrists, bipolar dis-
order researchers and IT experts, developed the MON-
ARCA system in close collaboration with patients with
bipolar disorder [25,26]. The MONARCA system in-
cluded a feedback loop on subjective self-monitored
measures between patients and clinicians and was tested
by the authors in multiple studies, this including a RCT
[20,27,28,31]. Subsequently a new version, the Mon-
senso system, was developed. The MONARCA II trial is
the first trial investigating the effect of electronic self-
monitoring of subjective measures including a feedback
loop integrating subjective as well as automatically gen-
erated behavioural data on measures of illness activity
on depressive and manic symptoms in patients with bi-
polar disorder.
Limitations
The intervention
The MONARCA II trial is designed to investigate the
effect of the total Monsenso system, comprising daily
self-monitoring of subjective measures and an integrated
feedback loop (based on either subjective self-monitored
measures or a combination of subjective self-monitored
measures and automatically generated data on measures of
illness activity) between patients and health care providers,
compared with using a smartphone for normal communi-
cative purposes. Thus, it will not be possible to address the
effect of the individual elements of the intervention.
The integrated feedback loop is based on prediction
models based on self-monitored subjective self-monitored
measures and for those smartphones capable of collecting
these data also on automatically generated behavioural
data on measures of illness activity. The integrated feed-
back loop and prediction models in the Monsenso system
are therefore not based on the same amount of data in the
two smartphone groups. The prediction models in the in-
tegrated feedback loop are adjusted during the trial period
(a learning model), due to increasing technical possibil-
ities, to achieve the best prediction possible.
The control group
As in any other non-pharmacological treatment trial is it
always a challenge to define a proper control group. The
MONARCA II trial is designed to include a control
group of patients using a smartphone for normal com-
municative purposes, a placebo smartphone. Automatic-
ally generated behavioural data on measures of illness
activity is collected on all patients using a smartphones
capable of collecting these data during the trial period,
including the patients in the control group, this allowing
for correlation analyses between depressive and manic
symptoms and the automatically generated behavioural
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patients with bipolar disorder.
Generalizability
A RCT represents a study design with possible high inter-
val validity, but this with a possible cost of lower external
validity and thereby lower generalizability of the study re-
sults. The MONARCA II trial recruits patients who have
received treatment at and been discharged from a tertiary
specialized mood disorder clinic, however including pa-
tients with recent onset of bipolar disorder, whom in most
countries are treated elsewhere. Further, the trial has a
pragmatic design with few exclusion criteria. In addition,
as the Monsenso system is user-friendly for both the pa-
tients and the health care providers, and previous MON-
ARCA studies showed a high acceptance and compliance
of the previous system [25-28], the findings of the MON-
ARCA II trial are believed to be generalizable to patients
with bipolar disorder in general.
Perspectives
Electronic monitoring using smartphones represents a
flexible and adjustable system that could be of great sup-
port for both patients and health care providers, and
possibly increase the patients’ illness insight, empower-
ment and awareness of early warning signs of upcoming
depressive or manic episodes.
If the Monsenso system is proved effective in reducing
the level of depressive and/or manic symptoms (and
other symptoms of bipolar disorder) and the rate of de-
pressive and manic episodes in the present trial, there
will be basis for extending the use of the system to the
treatment of patients with bipolar disorder in general
and in a larger scale. Potentially electronic monitoring
using smartphones may be applied in relation to patients
suffering from other mental disorders. In this way, it is
possible that outpatient treatment in general can be op-
timized, and that the frequency of necessary health care
provider/physician/clinician and other clinical staff visits
can be reduced and be more flexible according to the
needs of the patients.
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